Directly from the 8-k
The Company entered into a non binding Letter of Intent with a large Cellular Therapeutics and Storage Company located in the United States, for the acquisition of their storage samples rights, assets and business, contingent upon among other requirements, the Company's completion of due diligence, the execution of a binding definitive agreement, and the Company obtaining a firm commitment from an investment banker to provide the capital required by the Company to consummate the acquisition.
The executed Letter of Intent contemplates a purchase price of $30 million, of which $25 Million is to be paid in cash at closing, and the balance is to be paid in the form of Cord Blood America, Inc. stock valued at the stock's average closing price over the 20 days preceding the date of delivery, with $3 million in value in stock to be delivered 12 months after consummation of the acquisition, and $2 million in value in stock to be delivered 24 months after the consummation of the acquisition. If the total amount of stock to be delivered by the Company represents more than 25% of its outstanding capital stock after issuance, the Company retains the option to deliver cash rather than stock in order to cap the stock delivery at said 25%.
The Letter of Intent requires the identity of the target company to be kept confidential until a definitive acquisition agreement is executed. Cord Blood is currently in contact with its investment bankers, but there is no assurance that the Company will be successful in arranging the required firm commitment for the necessary capital on commercially reasonable terms. At this stage the only document that has been executed is the Letter of Intent, and it specifically states that it is non binding. Further, Cord Blood has initiated, but has not completed its due diligence. As a result, although management is optimistic, there can be no assurance that this contemplated acquisition will occur, and at this date there is no obligation on the Company's part to proceed.
My comments:
1. This acquisition must remain confidential. The last one announced had to be due to its relationship and agreement with another party.
2. The business perfectly complements CBAI's business model
3. The business is profitable from what we have seen in due diligence thus far.
4. We are aggressively pursuing closure to the transaction.
5. Within 12 months, by merging the two companies, this acquisition will make CBAI cash flow positive.
6. This acquisition, like the one previously announced and under binding LOI with CBAI, will bring CBAI a clear path to profitability.
7. For those keeping score, we have announced two acquisitions in the last four months that are different than the previous six acquisitions we made. The last six were either early stage opportunities to grow in emerging markets or the samples in storage alone provided a positive investment considering discounted cash flows.. We bought the assets and we reached a "mass" inflection point as a company. The acquisitions going forward that we are evaluating have to be at or near cash flow positive, and have to bring CBAI to cash flow positive within 12 months, or we won't look at them. As just mentioned, we now have two under LOI. We don't need to close both, only one. We'll pursue all of them though.
8. We understand the fear of further dilution. Let me clearly define the next 12 months. We have two courses of action to take. One is an acquisition that will be only executed through a financing instrument that will allow the company to be profitable within one year of the closing date, as this 8-k does. If not, we are not going to further dilute the shareholders with acquisitions that do not contribute to overall profitability We have two now that are active as are the financing arrangements to determine if this can work. The second course of action is not to make an acquisition, grow more measured, and reduce burn. It will not produce profits quickly. Either one, CBAI is focused on profits. We have been aggressive in the past and make no apologies for it. The future is to be determined by our ability to close one of the transactions and get their quickly, or to take a very slow, measured approach.
Many shareholders have asked to reveal the plan post recapitalization. One part of the plan revealed itself months ago, the first acquisition announced. Today a second piece of the puzzle is revealed.
My fellow shareholders, CBAI is more convinced than ever, that this industry is consolidating and that opportunity exists in abundance for those willing to be aggressive and we will pursue this growth and profitability strategy with vigor. We have been here before as a company, at a time of recapitalization, with a tremendous amount of negative sentiment. On the other side of the recapitalization, our stock thrived to its highest levels ever, peaking at an $80M market cap, our debts were reduced greatly, our acquisitions were made, our organic growth strategy implemented and our revenue stream diversification launched. The mass we needed as a company and the de-levering of the business were all accomplished.
CBAI sits here on the precipice of another great moment in time. We only see success ahead. You now have two pieces to the puzzle revealed, two very strong acquisitions in the funnel which bring us the clear path to profitability, and either one gets us there. As clearly executed before, a vote yes is a vote for growth.
Special Note: This website is intended to provide information to Cord Blood America Investors and Customers. The statements made are of opinion only by Matthew L. Schissler, Chairman & CEO of Cord Blood America. The information contained herein or any attachment contained herein does not constitute any kind of research report nor is it a recommendation to buy or sell any security mentioned herein whatsoever, and as such, it should not be construed to contain any research report analysis whatsoever. Regarding Forward-Looking Statements: Certain statements made during this presentation could be considered "forward-looking" statements within the meaning of the securities laws. These statements are subject to certain risks and uncertainties that could cause results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. CBAI disclaims any obligation to update any forward-looking statements. Some of the factors that may cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements are discussed in such public company's filings with the Securities and Exchange Commission
Statements made in this presentation, including, but not limited to, those relating to the goal of the company or subsidiaries, those relating to the private stem cell storage market's capacity grow in excess of $1 billion per year, our ability to experience growth as awareness of the industry increases, the broadened applications of stem cell therapeutics, our pricing structure remaining exclusive, the barriers to enter into the industry, the government's continued regulation of the industry, our assessment of our position in the market relative to our competitors, our projected financial performance and our anticipated future performance, are forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. Such forward-looking statements involve certain risks and uncertainties, without limitation, statements regarding the company's strategic direction, prospects and future results, our ability to increase income streams and to grow revenue and earnings. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. These statements are only predictions and are subject to certain risks, uncertainties and assumptions, which are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this document and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, events or circumstances after the date of such statement.
My EANDE
More Information
|
1 |
... |
225 |
226 |
|
228 |
229
Thread abonnieren
, allerdings ging der Kurs da immer steil nach oben. Wie hoch ist im Moment die Aktienanzahl? Es ist schon erstaunlich, aber geht mal auf Twitter und gebt unter Suche Cord blood america ein.....jeden Tag mind. 10 Treffer und alles Neue Info´s. Aber so wie es aussieht nur dazu da um neue Lemminge zu finden, die die Aktien abnehmen, die hier auf den Markt geschmissen werden. 
